---
title: "bioMérieux Gains FDA Clearance for New Gastrointestinal Panel"
date: "2025-02-11 14:33:30"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfoliobioMerieux ( (FR:BIM) ) has shared..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1061972606-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

bioMerieux ( [(FR:BIM)](https://www.tipranks.com/stocks/fr:bim) ) has shared an announcement.

bioMérieux has received U.S. FDA clearance for its BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid, a molecular test that detects 11 common gastrointestinal pathogens in about an hour. This new panel enhances the company’s diagnostic offerings by providing a faster and more comprehensive solution, which is expected to improve patient outcomes, streamline laboratory workflows, and strengthen bioMérieux’s position in syndromic molecular testing. It offers clinicians a choice between a 22-target and an 11-target panel, allowing for more precise treatment decisions and reduced empirical treatments.

**More about bioMerieux**

bioMérieux is a global leader in in vitro diagnostics, established in 1963 and operating in 45 countries. The company provides diagnostic solutions for infectious diseases and contamination detection in various sectors, including agri-food and pharmaceuticals. With a presence in over 160 countries and a vast distributor network, bioMérieux achieved revenues of €3.7 billion in 2023, with over 90% of sales occurring outside France.

**YTD Price Performance:** 10.61%

**Average Trading Volume:** 40,264

**Technical Sentiment Consensus Rating:** Sell

**Current Market Cap:** €13.39B

Learn more about BIM stock on [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/fr:bim/stock-analysis).

Trending Articles:
------------------

* [Super Micro Computer (SMCI) Stock Gains 18% Ahead of Earnings. Will the Momentum Continue?](https://www.tipranks.com/news/super-micro-computer-smci-stock-gains-18-ahead-of-earnings-will-the-momentum-continue)
* [Activist Elliott Ups Stake in Phillips 66 with Over $2.5B Investment](https://www.tipranks.com/news/activist-elliott-ups-stake-in-phillips-66-with-over-2-5b-investment)
* [‘Don’t Wait for the Dominoes to Fall,’ Says Top Investor About Palantir Stock](https://www.tipranks.com/news/dont-wait-for-the-dominoes-to-fall-says-top-investor-about-palantir-stock)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/biomerieux-gains-fda-clearance-for-new-gastrointestinal-panel)
